Meticuly
A deep-tech medical company specializing in AI-driven, 3D-printed patient-specific titanium bone implants and surgical solutions.
- CEO / Founder
- Andy Choi
- Team Size
- 51-200
- Stage
- Growth Stage
- Total Funding
- $8.65M
- Latest Round
- Series B (2021)
- Key Investors
- ["BE Healthcare Ventures","Expara","Digital Ventures","Chulalongkorn University Innovation Hub"]
Technology & Products
Key Products
["Craniomaxillofacial (CMF) Implants (Cranial, Facial, and Mandibular reconstruction)","Orthopedic Solutions (Patient-specific Hip and Spine implants)","AI-Powered Design Software (Proprietary digital platform for surgeon-led implant design)","Anatomical Models and Surgical Guides (3D-printed tools for pre-surgical planning)"]
Technological Advantage
Proprietary AI design modules significantly reduce the time required for custom implant engineering from weeks to days, supported by two FDA 510(k) clearances (2022 and 2024) for global commercial scalability.
Differentiation
Value Proposition
Delivers personalized, high-precision bone replacements with a rapid turnaround time, improving surgical accuracy and patient recovery while reducing operating room costs.
How They Differentiate
Meticuly differentiates through its proprietary AI-driven design platform that automates the creation of patient-specific implants, reducing the design-to-delivery cycle from weeks to just a few days. This digital-first workflow offers higher precision and significantly lower costs compared to traditional manual design processes used by global incumbents.
Market & Competition
Target Customers
Orthopedic and neurosurgeons, specialized medical institutions, and private/public hospital networks.
Industry Verticals
["Healthcare","Medical Devices","Additive Manufacturing (3D Printing)","Artificial Intelligence"]
Competitors
Materialise, Anatomics, Stryker (Patient Specific Solutions)
Growth & Milestones
Growth Metrics
Partnered with over 150 hospitals worldwide; holds 70+ global intellectual properties; secured two separate FDA 510(k) clearances for global market scalability.
Major Milestones
["Secured first FDA 510(k) clearance for Craniomaxillofacial (CMF) implants in 2022","Successfully closed Series B funding round in January 2024","Secured second FDA 510(k) clearance for Orthopedic and Spine solutions in 2024","Recognized as a WIPO IP Champion and selected for global showcase at Expo 2025 Osaka"]
Notable Customers
Chulalongkorn Hospital, Siriraj Hospital, Bumrungrad International Hospital, Faculty of Medicine Ramathibodi Hospital